Anticancer effects of licofelone (ML-3000) in prostate cancer cells

Anticancer Research

Volumn 27, Issue 4 B, 2007, Pages 2393-2402

  Narayanan, Narayanan K ^a   Nargi, Dominic ^a   Attur, Mukundan ^b   Abramson, Steven B ^a,b   Narayanan, Bhagavathi A ^a  

^a NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b NYU HOSPITAL FOR JOINT DISEASES   (United States)

Author keywords

COX LOX inhibitor; Licofelone; NSAIDs; Prostate cancer; TRAMP

Indexed keywords

ARACHIDONATE 5 LIPOXYGENASE; CYCLOOXYGENASE 2; LICOFELONE;

APOPTOSIS; ARTICLE; CANCER CELL; CELL GROWTH; CELL VIABILITY; CHEMOPROPHYLAXIS; CONTROLLED STUDY; DOSE RESPONSE; DOWN REGULATION; DRUG INHIBITION; HORMONE DEPENDENCE; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN EXPRESSION;

ACETIC ACIDS; ADENOCARCINOMA; ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; ARACHIDONATE 5-LIPOXYGENASE; CELL GROWTH PROCESSES; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITORS; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; MALE; MICE; MICE, TRANSGENIC; PROSTATIC NEOPLASMS; PYRROLES; RNA, MESSENGER; TRANSCRIPTION, GENETIC; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 34547736054     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (39)

1. Jemal A, Siegel R, Ward E, Murray T, Xu J, Smigal C and Thun MJ: Cancer statistics 2006. CA Cancer J Clin 56: 106-130, 2006.
2. Hsing AW and Chokkalingam AP: Prostate cancer epidemiology. Front Biosci 11: 1388-1413, 2006.
3. Powell IJ: Epidemiology and pathophysiology of prostate cancer in African-American men. J Urol 77: 444-449, 2007.
4. Kelloff GJ, Lieberman R, Steele VE, Boone CW, Lubet RA, Kopelovich L, Malone WA, Crowell JA, Higley HR and Sigman CC: Agents, biomarkers, and cohorts for chemopreventive agent development in prostate cancer. Urology 57: 46-51, 2001.
5. Norrish AE, Jackson RT and McRae CU: Non-steroidal antiinflammatory drugs and prostate cancer progression. Int J Cancer 77: 511-515, 1998.
6. Nelson JE and Harris RE: Inverse association of prostate cancer and non-steroidal anti-inflammatory drugs (NSAIDs): results of a case-control study. Oncol Rep 7: 169-170, 2000.
7. Waskewich C, Blumenthal RD, Li H, Stein R, Goldenberg DM and Burton J: Celecoxib exhibits the greatest potency amongst cyclooxygenase (COX) inhibitors for growth inhibition of COX-2-negative hematopoietic and epithelial cell lines. Cancer Res 62: 2029-2033, 2002.
8. Solomon SD, McMurray JJ, Pfeffer MA, Wittes J, Fowler R, Finn P, Anderson WF, Zauber A, Hawk E and Bertagnolli M: Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention. N Eng J Med 353: 1071-1080, 2005.
9. Solomon SD: Cyclooxygenase-2 inhibitors and cardiovascular risk. Curr Opin Cardiol 21: 613-617, 2006.
10. Shappell SB, Manning S, Boeglin WE, Guan YF, Roberts RL, Davis L, Olson SJ, Jack GS, Coffey CS, Wheeler TM, Breyer MD and Brash AR: Alterations in lipoxygenase and cyclooxygenase-2 catalytic activity and mRNA expression in prostate carcinoma. Neoplasia 3: 287-303, 2001.
11. Jack GS, Brash AR, Olson SJ, Manning S, Coffey CS, Smith JA Jr and Shappell SB: Reduced 15-lipoxygenase-2 immunostaining in prostate adenocarcinoma: correlation with grade and expression in high-grade prostatic intraepithelial neoplasia. Hum Pathol 31: 1146-1154, 2000.
12. Marcouiller P, Pelletier JP, Guevremont M, Martel-Pelletier J, Ranger P, Laufer S and Reboul P: Leukotriene and prostaglandin synthesis pathways in osteoarthritic synovial membranes: regulating factors for interleukin 1beta synthesis. J Rheumatol 32: 704-712, 2005.
13. Singh VP, Patil CS and Kulkarni SK: Effect of licofelone against NSAIDs-induced gastrointestinal ulceration and inflammation. Indian J Exp Biol 43: 247-253, 2005.
14. Ulbrich H, Soehnlein O, Xie X, Eriksson EE, Lindbom L, Albrecht W, Laufer S and Dannhardt G: Licofelone, a novel 5-LOX/COX-inhibitor, attenuates leukocyte rolling and adhesion on endothelium under flow. Biochem Pharmacol 70: 30-36, 2005.
15. Laufer S, Augustin J, Dannhardt G and Kiefer W: (6,7- Diaryldihydropyrrolizin-5-yl) acetic acids, a novel class of potent dual inhibitors of both cyclooxygenase and 5-lipoxygenase. J Med Chem 37: 1894-1897, 1994.
16. Laufer S, Tries SJ, Augustin J and Dannhardt G: Pharmacological profile of a new pyrrolizine derivative inhibiting the enzymes cyclo-oxygenase and 5-lipoxygenase, Arzneim.-Forsch./Drug Res 44: 629-636, 1994.
17. Cicero AFG, Derosa G and Gaddi A: Combined lipoxygenase/cyclo-oxygenase inhibition in the elderly: the example of licofelone. Drugs Aging 22: 393-403, 2005.
18. Hampton T: Arthritis clinical trial results revealed. JAMA 297: 28-29, 2007.
19. Shureiqi I, Chen D, Lotan R, Yang P, Newman RA, Fischer SM and Lippman SM: 15-lipoxygenase-1 mediates nonsteroidal anti-inflammatory drug-induced apoptosis independently of cyclooxygenase-2 in colon cancer cells. Cancer Res 60: 6846-6850, 2000.
20. Bias P, Buchner A, Klesser B and Laufer S: The gastrointestinal tolerability of the LOX/COX inhibitor, licofelone, is similar to placebo and superior to naproxen therapy in healthy volunteers: results from a randomized, controlled trial. Am J Gastroenterol 99: 611-618, 2004.
21. Hayward SW, Dahiya R, Cunha GR, Bartek J, Deshpande N and Narayan P: Establishment and characterization of an immortalized but non-transformed human prostate epithelial cell line: BPH-1. In Vitro Cell Dev Biol Anim 31: 14-24, 1995.
22. Narayanan NK, Narayanan BA and Reddy BS: A combination of docosahexaenoic acid and celecoxib prevents prostate cancer cell growth in vitro and is associated with modulation of nuclear factor-kappa B, and steroid hormone receptors. Int J Oncol 26: 785-792, 2005.
23. Narayanan BA, Narayanan NK, Davis L and Nargi D: RNA interference- mediated cyclooxygenase-2 inhibition prevents prostate cancer cell growth and induces differentiation: modulation of neuronal protein synaptophysin, cyclin D1, and androgen receptor. Mol Cancer Ther 5: 1117-1125, 2006.
24. Foster BA, Kaplan PJ and Greenberg NM: Peptide growth factors and prostate cancer: new models, new opportunities. Cancer Metastasis Rev 17: 317-324, 1998.
25. Tries S, Neupert W and Laufer S: The mechanism of action of the new antiinflammatory compound ML3000: inhibition of 5-LOX and COX-1/2. Inflamm Res 51: 135-143, 2002.
26. Boileau C, Peiletier JP, Tardif G, Fahmi H, Laufer S, Lavigne M and Martel-Pelletier J: The regulation of human MMP-13 by licofelone, an inhibitor of cyclo-oxygenases and 5-lipoxygenase, in human osteoarthritic chondrocytes is mediated by the inhibition of the p38 MAP kinase signalling pathway. Ann Rheumatic Diseases 64: 891-898, 2005.
27. Smolka AJ, Goldenring JR, Gupta S and Hammond CE: Inhibition of gastric H,K-ATPase activity and gastric epithelial cell IL-8 secretion by the pyrrolizine derivative ML 3000. BMC Gastroenterol 4: 1-11, 2004.
28. Narayanan BA, Narayanan NK, Pittman P and Reddy BS: Adenocarcina of the mouse prostate growth inhibition by celecoxib: downregulation of transcription factors involved in COX-2 inhibition. Prostate 66: 257-265, 2006.
29. Narayanan NK, Narayanan BA, Bosland MC, Condon MS and Nargi D: Docosahexaenoic acid in combination with celecoxib modulates HSP70 and p53 proteins in prostate cancer cells. Intl J Cancer 119: 1586-1598, 2006.
30. Miller RG: Simultaneous Statistical Inference. 2nd edition. New York: Springer-Verlag, p. 37, 1981.
31. Singh RP and Agarwal R: Mechanisms of action of novel agents for prostate cancer chemoprevention. Endocr Relat Cancer 13: 751-778, 2006.
32. Basler JW and Piazza GA: Nonsteroidal anti-inflammatory drugs and cyclooxygenase-2 selective inhibitors for prostate cancer chemoprevention. J Urol 171: S59-62, 2004.
33. Kelloff GJ, Lieberman R, Steele VE, Boone CW, Lubet RA, Kopelovich L, Malone WA, Crowell JA, Higley HR and Sigman CC: Agents, biomarkers, and cohorts for chemopreventive agent development in prostate cancer. Urology 57: 46-51, 2001.
34. Sabichi AL and Lippman SM: COX-2 inhibitors and other NSAIDs in bladder and prostate cancer. Prog Exp Tumor Res 37: 163-178, 2003.
35. Steele VE, Moon RC, Lubet RA, Grubbs CJ, Reddy BS, Wargovich M, McCormick DL, Pereira MA, Crowell JA, Bagheri D, Sigman CC, Boone CW and Kelloff GJ: Preclinical efficacy evaluation of potential chemopreventive agents in animal carcinogenesis models: methods and results from the NCI Chemoprevention Drug Development Program. J Cell Biochem Suppl 20: 32-54, 1994.
36. Narayanan BA: Chemopreventive agents alters global gene expression pattern: Predicting their mode of action and targets. Curr Cancer Drug Targets 6: 711-728, 2006.
37. Gaytan M, Bellido C, Morales C, Sanchez-Criado JE and Gaytan F: Effects of selective inhibition of cyclooxygenase and lipooxygenase pathways in follicle rupture and ovulation in the rat. Reproduction 132: 571-577, 2006.
38. Julemont F, Dogne JM, Pirotte B and de Leval X: Recent development in the field of dual COX / 5-LOX inhibitors. Mini Rev Med Chem 4: 633-638, 2004.
39. Clark TP: The clinical pharmacology of cyclooxygenase-2-selective and dual inhibitors. Vet Clin North Am Small Anim Pract 36: 1061-1085, 2006.